It's not too often that you see a biotech company establish a truly
differentiated product portfolio with multi-billion dollar potential and
minimal competition, but Vertex (Nasdaq:VRTX)
seems to be doing exactly that. This one-time specialist in virology is
already well on the way to more than $5 billion in potential revenue,
and could ultimately see nearly double that amount if clinical trials go
the right way. This may ultimately put the company in the “nice problem
to have” category of figuring out how to reinvest the proceeds and
determining whether or not further investments in the hepatitis C
program are worthwhile.
Please continue here:
http://www.investopedia.com/stock-analysis/082813/vertex-building-fortress-cystic-fibrosis-vrtx-gild-gsk-bmy.aspx
No comments:
Post a Comment